A shot in the arm for vaccine safety surveillance

Boost your national vaccine safety surveillance with VigiFlow.

Want to know more?

Write to us at vigibase@who-umc.org 

Monitoring adverse events following immunisation (AEFI) is essential to securing the safety of vaccines.

VigiFlow supports national vaccine safety surveillance, allowing rapid identification of any safety concerns associated with vaccines.

In collaboration with WHO and other stakeholders, UMC has expanded VigiFlow to support reporting and analysis of AEFI for immunisation programmes (at national and subnational levels).

The AEFI expansion facilitates data capture, including the core variables for AEFI, and AEFI analysis from a customised line listing. VigiFlow also supports statistical reporting and controlled sharing of reports with the WHO Programme for International Drug Monitoring (WHO PIDM).

Available as an add-on module to VigiFlow, VigiMobile makes it easier for health workers to collect AEFI data. Using their mobile devices, they can fill in and submit reports to VigiFlow for further review, assessment and analysis.

Training and more information on VigiFlow AEFI support can be found in this quick start guide, as well as a series of short videos demonstrating how to enter and analyse AEFI data in VigiFlow. Additionally, recordings of training webinars focusing on the new data entry form, WHODrug coding aspects of COVID-19 vaccines, and the AEFI line listing are available here:

Through the secure and controlled sharing of information from VigiFlow to VigiBase, VigiLyze supports investigation of safety concerns using national, regional and global data. The latest developments in VigiLyze and improvements to vaccine safety surveillance allow members of the WHO PIDM to now do more advanced statistical signal detection, vaccine by vaccine, as well as analyse different vaccine platforms. Read more about VigiLyze here.


In the spotlight: Vaccine safety in the WHO PIDM

Last modified on: April 15, 2024